期刊文献+

CT导向下^(125)I粒子植入治疗肝门区肝癌 被引量:71

CT guided radioactive seed ^(125)I implantation in treating hilar hepatic tumor and metastatic lymphnodes
下载PDF
导出
摘要 目的评价CT导向下125I粒子植入治疗肝门区肝癌及淋巴结的临床价值。方法本组病例32例,其中肝门区肝细胞癌(HCC)8例,肝门区胆管癌(HC)12例,肝转移瘤6例,肝门区淋巴结转移6例。14例侵犯肝门胆管致肝内胆管扩张,22例合并肝硬化。全部病例经CT、MRI检查或病理穿刺活检证实。病灶平均直径为4.2 cm。采用TPS计算布源,在CT导向下将125I粒子植入瘤灶内,采用0.6~0.9 mCi活度的125I粒子相隔1.0~1.5 cm平面播植。结果2例死于远处转移,3例死于肝功能衰竭,全组中位生存时间10个月。2个月后CT复查,完全缓解(CR)2例;部分缓解(PR)20例;无变化(NC)5例;进展(PD)5例。总有效率(CR+PR)68.8%。2个月随访过程中发现7颗粒子在肝脏内游走,3颗粒子迁徙至肺内;1例出现气胸,肺压缩在30%以下,白细胞轻度下降1例。未见大出血、胆汁瘘、肠瘘、肠出血等严重并发症。结论CT导向下放射性粒子植入治疗肝门区肿瘤及淋巴结创伤小,并发症发生率低,生活质量改善明显,近期效果好,是治疗中晚期肝门区肿瘤及淋巴结的简单、安全、有效的方法。 Objective To investigate the clinical value of CT guided radioactive seed ^125Ⅰ implantation in treating hilar hepatic tumor and metastatic lymphnodes. Methods 32 patients with pancreatic cancer accepted CT guided radioactive seeds ^125Ⅰ implantation were enrolled in this study. The average tumor dimension was 4.2 cm. In this series, there were 8 cases of hepatocellular carcinoma, 12 cases of hilar cholangio carcinoma,6 cases of hepatic metastasis and 6 of hepatic hilar tumor and metastatic lymphnodes. Among these patients, 14 cases had cholangiectasis and 22 cases had cirrhosis. Under CT guidance, ^125Ⅰ seeds of 0.6-0.9 mCi were implanted into the pancreatic cancer at a distance of 1.0-1.5 cm according to TPS. Results Two cases died on account of metastasis and three died through liver function failure. Among CT followed-up of 32 patients in 2 months, 2 obtained CR, 20 obtained PR, 5 NC and 5 PD. The responsive rate was 68.8%. The side effects occurred during the procedure including pneumothorax in 1 case with lung compression less than 30% ; 7 seeds migration in liver and 3 seeds in lung. WBC decreased slightly in 1 cases during 2 months follow up. No massive bleeding, biliary fistula, intestinal fistula, intestinal hemorrhage, acute pancreatitis, enterorrhagia and intra-abdominal abscess were encountered. Conchlsions CT guided radioactive seed ^125Ⅰ implantation procedure is a safe and effective method in treating hilar hepatic tumor and metastatic lymphnodes with good clinical effects of minimal damage and few complications.
出处 《介入放射学杂志》 CSCD 2005年第6期606-609,共4页 Journal of Interventional Radiology
关键词 碘放射性核素 放射学 介入性 近距离放射疗法 肝门区肿瘤及淋巴结 评价研究 lodineradioisotopes Radiology, interventional Brachytherapy Hilar hepatic tumor and lymphonode Evaluation studies
  • 相关文献

参考文献6

  • 1Peretz T,Nori D,Nilaris B,et al.Treatment of primary unresectable carcinoma of the pancreas with 125I implantation.Int J Radiat Oncol Biol Phys ,1989 ,17:931-935.
  • 2Martinez MR,Nag S,Nieroda CA ,et al.Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver.Cancer ,1999 ,85 :1218-1225.
  • 3C.Clifton ling.Permanent implants using Au-198 ,Pd-103 and I-125:Radiobiological considerations based on the linear quadratic model.Int J Radiat Oncol Biol Phys ,1992 ,23:81-87.
  • 4黄振国,张雪哲,王武,洛小林,王继英.CT导引下^(125)I粒子植入在治疗恶性肿瘤中的应用[J].中华放射学杂志,2004,38(9):921-925. 被引量:135
  • 5Xiao XW.The relationship between survival and relativity factors in schistosomiasis patients with large intestional carcinoma liver metastasis Chinese J Parasitic Disesse Control ,1999; 12:40-45.
  • 6Martinez-Monge R,Nag S,Edward W ,et al.125I brachytherapy for colorectal adenocarcinoma recurrent in pelvis and paraortics.Int J Radaition Oncology Bio Phys,1998,42 ;545-550.

二级参考文献12

  • 1Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys,2000,47:1261-1266.
  • 2Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys,1997,39:347-353.
  • 3Molloy JA, Williams MB. Treatment planning considerations and quality assurance for CT-guided transischiorectal implantation of the prostate. Med Phys,1999,26:1943-1951.
  • 4Martinez-Monge R, Nag S, Nieroda CA, et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer,1999,85:1218-1225.
  • 5Vikram B, Mishra S.Permanent iodine-125 implants in postoperative radiotherapy for head and neck cancer with positive surgical margins. Head Neck,1994,16:155-157.
  • 6Kumar PP, Patil AA, Leibrock LG,et al. Continuous low dose rate brachytherapy with high activity iodine-125 seeds in the management of meningiomas. Int J Radiat Oncol Biol Phys,1993,25:325-328.
  • 7Lee DJ, Liberman FZ, Park RI, et al. Intraoperative I-125 seed implantation for extensive recurrent head and neck carcinomas. Radiology,1991,178:879-882.
  • 8Heelan RT, Hilaris BS, Anderson LL, et al. Lung tumors: percutaneous implantation of I-125 sources with CT treatment planning. Radiology, 1987,164:735-740.
  • 9Lee W, Daly BD, DiPetrillo TA, et al. Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg,2003,75:237-243.
  • 10Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys, 2003,56:1085-1092.

共引文献134

同被引文献576

引证文献71

二级引证文献476

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部